It is very important to examine the influence of inhibition of in situ estrogen production on the pathobiology of human sex steroid-dependent tumors in order to understand the clinical effects of aromatase inhibitors. We have examined the biological changes before and after aromatase inhibitor treatment in vitro (endometrial and ovarian cancer) and in vivo (breast cancer). First, we analyzed these changes using histoculture of 15 human endometrial cancers and 9 ovarian cancers. Five of the fifteen endometrial cancers and four of the nine ovarian cancers demonstrated decreased [
Introduction
An increasing number of aromatase inhibitors are being introduced into clinical practice (Dowsett 1996 (Dowsett , 1997 . These inhibitors are at present considered to act on sex steroid-dependent neoplasms by suppressing intratumoral aromatase activity, i.e. depletion of in situ estrogen production which results in impaired estrogenic stimulation is an important mechanism in the antitumor activity of aromatase inhibitors (de Jong et al. 1997) . Newly developed aromatase inhibitors are specific and associated with minimum side effects (Dowsett 1996 (Dowsett , 1997 . Very recently, one of these newly developed aromatase inhibitors has been shown to exert a more potent antitumor activity compared with other antiestrogens including tamoxifen (Brodie a et al. 1998) . However, there are two important factors which should be clarified when aromatase inhibitors are used as a treatment for patients with human sex steroid-dependent malignancies including breast cancer. One is the pretreatment analysis of possible responsiveness or resistance to inhibitors using surgical pathology specimens of carcinomas. The other is the exact mechanism of antitumor effects of aromatase inhibitors on carcinoma cells. An analysis of biological and/or pathological features of human sex steroid-dependent carcinoma cases following treatment with aromatase inhibitors and the comparison of these findings with those prior to treatment can provide very important information relating to the problems described above. Therefore, we examined the changes in aromatase activity, aromatase, 17β-hydroxysteroid dehydrogenase type I, and/or [ 3 H]thymidine uptake and estrogen receptor α (ER) immunolocalization, cell proliferation examined by Ki67 immunostain, and apoptosis using the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method before and after treatment with aromatase inhibitors in human breast cancer tissues of the same patients and in histoculture of human endometrial and ovarian carcinoma.
Histoculture of endometrial and ovarian carcinoma
The recent development of histoculture or threedimensional gel-supported primary culture allows the growth of various kinds of normal and neoplastic human tissues (Sasano et al. 1996a -e, Brodie et al. 1998 , Nakamura et al. 1998 . Primary culture of human sex steroid-dependent neoplasms has generally been performed by dispersing the cells but these attempts have suffered from difficulty in the long term growth of these human tumors and in maintaining their in vivo structural and functional properties. Intratumoral aromatase is present in stromal or interstitial cells, not in parenchymal cells in most human breast , 1996a ,b, Sasano & Ozaki 1997 , endometrial (Sasano 1994 , Watanabe et al. 1995 , Sasano et al. 1996c ) and ovarian (Kaga et al. 1996 , Sasano et al. 1996d , Sasano & Harada 1998 malignancies. Therefore, stromal and parenchymal cells of human sex steroid-dependent neoplasms should be co-cultured in order to examine intratumoral aromatase in vitro. In this regard, a three-dimensional collagen gelsupported histoculture system, which allows tissues to be cultured with the preservation of native-state architecture and functions (Vescio et al. 1987 , Hoffman 1992 , is an ideal method of examining the in vitro effects of aromatase inhibitors on the pathobiology of human neoplasms. In addition, Hoffman and colleagues reported that the histoculture drug response assay system can provide important information on evaluating antitumor effects of chemotherapeutic agents for many kinds of human malignancies (Vescio et al. 1987 , Hoffman 1991 , 1992 . We have previously reported a successful application of the histoculture drug response assay for predicting the antitumor effects of aromatase inhibitors in patients with breast cancer (Nakamura et al. 1998) . In this study, we applied this assay to human endometrial and ovarian cancers and examined the changes of various biological features before and after aromatase inhibitor treatment.
Materials and Methods

Reagents and chemicals for histoculture
Fetal calf serum was purchased from Gibco BRL (Gaithersburg, MD, USA), [methyl- 3 H]thymidine (70-90
Ci/mmol) was obtained from NEN Dupont (Boston, MA, USA), and Spongostan was purchased from Ferrosan (Copenhagen, Denmark). NKS01 (14α-hydroxy-4-androstene-3,6,17-trione) is an aromatase inhibitor described previously by Yoshihama et al. (1989) . Other chemicals for histoculture assay were purchased from Sigma (St Louis, MO, USA).
Immunohistochemistry
The collagen gels were fixed in 10% formalin for 18 h at 4 °C (Sasano et al. 1996e ) and the immunohistochemical procedure was performed on fixed collagen gel in 14/15 endometrial cancer cases and 7/9 ovarian cancer cases.
Immunohistochemical analysis was performed as previously reported , 1996c , 1996d , Sasano & Ozaki 1997 . Immunostaining was performed using the Histofine system (Nichirei Co. Ltd, Tokyo, Japan). The labeling index or the percentage of tumor cells positive for Ki67 and ER was obtained as previously described , 1996a ,b, Sasano & Ozaki 1997 . Statistical analysis was performed using Scheffe or Bonferroni analysis in order to compare the immunolocalization findings in the control group, those receiving testosterone (testosterone addition) and those receiving aromatase inhibitors with or without testosterone in the histoculture drug response assay.
Histoculture drug response assay
Fifteen endometrial cancer tissue specimens and nine ovarian cancer tissue specimens were obtained from patients at the Tohoku University Hospital and they were immediately rinsed with 0.1 M phosphate buffered saline. Endometrial carcinomas were all of the endometrioid type and ovarian carcinomas were all of the common epithelial type. The specimens were cut into 1-2 mm cubes and four or five pieces were placed on the surface of each absorbable gelatin sponge (Spongostan). They were then incubated in a 24-well plate and microplated in 1 ml Eagle's minimal essential medium per well without phenol red and with 5% charcoal-dextran-treated fetal calf serum containing (1) vehicle, (2) testosterone (10 -6 M), (3) an aromatase inhibitor, NKS01 (10 -6 M), and There were no significant differences in patterns of aromatase immunolocalization, Ki67 and ER labeling index among the control, testosterone treated, and aromatase inhibitors with or without testosterone groups in the histoculture drug response assay.
testosterone plus NKS01. Cultures were maintained at 39°C in 5% CO 2 . After 7 days, the tissue blocks were transferred to new sponges and incubated in [ 3 H]thymidine-labeling medium (2 µCi/ml/well) for 3 days. The tissue blocks were transferred to 1.5 ml microtube, and 0.5 ml collagenase solution (0.1 mg/ml in 10 mM TE buffer) was added and incubated at 37 °C overnight. After the collagenase solution was discarded, 0.1 ml proteinase K solution (0.1 mg/ml in 10 mM TE, 0.5 SDS) was added to the tube and incubated at 37 °C for 2-3 h. Then DNA was extracted and dissolved in 0.05 ml TE (pH 7.8). The amount of DNA was quantitated by spectrophotometer (OD260), and the radioactivity of [ 3 H]thymidine incorporated into DNA was measured in a liquid scintillation spectrometer.
Results and Discussion
The results are summarized in Tables 1 and 2 .
Aromatase immunoreactivity was detected in the stromal cells in 6/14 cases of endometrial carcinomas and 5/7 cases of ovarian carcinomas. The cases in which aromatase immunoreactivity was detected in the stromal cells of primary tumors or in surgical pathology specimens also demonstrated aromatase immunoreactivity in stromal cells of carcinoma tissues of untreated histoculture and vice versa. These findings confirmed that the histoculture system maintains the capacity of in situ steroid production as reported in human breast carcinoma (Nakamura et al. 1998 ) and testicular Leydig cell tumor (Sasano et al. 1996e ). The addition of testosterone, a substrate for aromatase, resulted in an increment of aromatase in two There were no significant differences in the pattern of aromatase immunolocalization, Ki67 and ER labeling index among the control, testosterone treated and aromatase inhibitors with or without testosterone groups in the histoculture drug response assay.
cases of endometrial cancer and none of ovarian cancer but the Ki67 labeling index of tumor cells increased in five cases of endometrial cancer and in three cases of ovarian cancer, which suggests that the histoculture system maintains the capacity of induction of aromatase by testosterone in these human ovarian and endometrial carcinomas. Induction of intratumoral aromatase results in increased cell proliferation of tumor cells in some of these cases as reported in breast cancers (Nakamura et al. 1998 ). An aromatase inhibitor, NKS01, blocked the [ 3 H]thymidine incorporation stimulated by testosterone to control levels in 4/15 endometrioid carcinomas and 4/9 ovarian carcinomas and decreased the Ki67 labeling index in 10 endometrial carcinoma cases and in 7 ovarian carcinoma cases, although these differences in Ki67 labeling index did not reach statistical significance. These results also indicate that depletion of in situ tumor estrogen through inhibition of intratumoral aromatase may result in decreased cell proliferation of tumor cells in human endometrial and ovarian carcinoma. The decreased cell proliferation due to aromatase inhibitors observed in these in vitro analyses appears not to be directly related to intratumoral aromatase and estrogen receptor status in endometrial and ovarian carcinomas in contrast to breast carcinoma (Nakamura et al. 1998) .
There were no significant differences in the ER labeling index among the control, testosterone treated and those treated with aromatase inhibitors with or without testosterone in the histoculture drug response assay. These findings suggest that aromatase inhibitor treatment did not change estrogen receptor status of tumor cells in human endometrial and ovarian carcinomas. The histoculture system may provide important information on the analysis of efficacy or the effects of various aromatase inhibitors in various human sex steroid-dependent neoplasms.
Breast cancer
In situ synthesis of estrogen in breast tumors, as opposed to peripheral aromatization and uptake from plasma can enhance tissue estradiol (E 2 ) levels and stimulate tumor growth (Reed et al. 1989) . Therefore, it is important to study pathobiological features of breast cancer tissues following depletion of tumor estrogen caused by impairment of in situ intratumoral aromatization because aromatase inhibitors are most frequently used in the patients with breast cancer among human sex steroiddependent neoplasms. However, this has not been well studied, in contrast to numerous investigations of the clinical efficacy of aromatase inhibitors in patients with breast carcinoma. Reed et al. (1989) reported a decrease in DNA polymerase alpha activity in 4/6 breast cancer cases after treatment with 4-hydroxyandrostenedione, although there was no significant correlation between the level of [ 3 H]estrone formed in situ and DNA polymerase activity. We also reported a decrease in [ 3 H]thymidine incorporation in histoculture of human breast carcinoma (Nakamura et al. 1998) . However, features other than cell proliferation including the possible effects of aromatase inhibitors on intratumoral aromatase expression have not been studied. In this study, we examined pathobiological features of the same breast carcinoma before and after treatment with aromatase inhibitors in six patients.
Materials and methods
We examined six surgical pathology specimens of the breast carcinoma before and after treatment with aromatase inhibitors (Table 3 ). The aromatase inhibitors employed were aminoglutethimide 500 mg per day plus 40 mg hydrocortisone orally in three cases (cases 1, 2 and 3), and 4-hydroxyandrostenedione 250 mg intramuscular injection at 14-day intervals in the other three cases. Patients were either T2 or T3, N0 or N1 and M0 according to TNM classification and greater than 60 years old and postmenopausal. Aromatase in vitro activity of the tumor specimens was determined as described previously (Miller & O'Neil 1987) . Immuno-histochemistry and its evaluation were performed as described above. TUNEL was performed as described previously .
Results and discussion
The results are summarized in Table 3 . Aromatase activity and immunoreactivity increased after treatment in the three cases treated with aminoglutethimide despite a clinical response to the treatment in one of these three cases. Aromatase immunoreactivity in both intratumoral stromal cells and adipocytes was the same or decreased in all but one case (case 4 in Table 3 ). The patterns of the changes of 17β-hydroxysteroid dehydrogenase type I, which converts estrone to estradiol in carcinoma cells and adjacent adipocytes, and of ERα and progesterone receptor before and after treatment with aromatase inhibitors were not consistent. This paradoxical increase in aromatase activity and/or expression after treatment with aromatase inhibitors, especially that of aminoglutethimide, was also reported by Miller and O'Neill (1987) in breast cancer and by Coate and Resko (1996) in guinea pig brain after letrozole treatment. These paradoxical effects may be due to a reversible association of aminoglutethimide with aromatase, which may influence turn-over rates of aromatase, or to an autoregulatory mechanism of intratumoral aromatase which is interrupted by enzyme inhibition, but further investigations are needed to clarify this point. Impairment of in situ estrogen production is Histological grade was assessed in invasive ductal carcinoma according to the criteria of Elston and Ellis (1991) as previously described. TUB, NP, and MC ranged from 1-3. The scores of these categories were added and the overall histological grade (HG) was determined as follows: 3-5 points, I (grade I), well differentiated; 6-7 points, II (grade II), moderately differentiated; 8-9 points, III (grade III), poorly differentiated. Necrosis, desmoplasia and hyalinosis were graded as: 0, none; 1+, mild; 2+, moderate; 3+, marked.
considered to result in the decrease of estrogen-dependent tumor cells and the increase of estrogen-independent tumor cells, possibly because impairment of in situ estrogen biosynthesis may preferentially suppress estrogen receptor positive tumor cells while not affecting the proliferative activity of estrogen receptor negative tumor cells. However, a marked decrease in estrogen receptor positive tumor cells was detected only in 1/5 cases. Therefore, although the number of cases was limited in our study, it appears that the aromatase inhibitors may not influence the proportion of estrogen receptor positive tumor cells in human breast cancer. These results may also indicate that treatment with aromatase inhibitors by no means results in promoting the proliferation of clones of estrogen-independent carcinoma cells.
As it was reported in previous studies of the effects of aromatase inhibitors on proliferative activity of human breast carcinoma (Nakamura et al. 1998 , the Ki67 labeling index in breast carcinoma tissues, which represents the proportion of proliferative tumor cells, decreased after treatment with aromatase inhibitors in 5/6 cases examined. What is more interesting, TUNELpositive tumor cells, in which the great majority are considered to be those undergoing apoptosis, markedly increased in number after treatment with aromatase inhibitors in 4/6 cases. In addition, treatment with aromatase inhibitors results not only in increased coagulative necrosis as detected in chemotherapy, but also in extensive hyalinosis, one of the degenerative processes of carcinoma tissues, with or without foreign body reaction. These results suggest that aromatase inhibitors, at least aminoglutethimide and 4-hydroxyandrostenedione are considered to exert antitumor effects through decreasing cell proliferation and increasing apoptosis of the carcinoma cells, which may result in degeneration of carcinoma tissues. It awaits further investigations to clarify the possible correlation of host reaction such as tumor infiltration lymphocytes and/or macrophages or angiogenesis and effects of aromatase inhibitors in human breast carcinoma tissues.
